Orsini Specialty Pharmacy Continues Expansion Through Strategic Partnership

Orsini Specialty Pharmacy (Orsini), the leading independent specialty pharmacy focused on rare diseases, gene therapies and complex conditions, funds managed by global investment firm Carlyle, and Consonance Capital Partners, a healthcare-focused private equity firm, recently announced a strategic partnership to position Orsini to further expand patient access to therapies that treat rare diseases and chronic conditions. Terms of the transaction were not disclosed.

Providing patients with comprehensive and compassionate care since 1987, Orsini’s high-touch model centers around experienced, therapy-specific care teams that provide personalized care to patients based on their specific conditions and treatments.

The company’s comprehensive solutions include medication adherence programs, data analytics, customized manufacturer programs, and nationwide nursing coverage for convenient in-home infusion services.

The company’s comprehensive solutions include medication adherence programs, data analytics, customized manufacturer programs, and nationwide nursing coverage for convenient in-home infusion services.

Headquartered in Elk Grove Village, IL, Orsini Specialty Pharmacy holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, NABP, and ACHC’s Distinction in Rare Diseases and Orphan Drugs. Orsini is one of only six specialty pharmacies to be awarded the Distinction in Rare Diseases and Orphan Drugs by the Accreditation Commission for Health Care (ACHC).

Takeaway: Consonance Capital Partners previously completed the recapitalization of Orsini in 2019 in partnership with the company’s CEO and President, Michael Fieri